- Once a Blockbuster Prospect, Is Travere’s Kidney Drug on Track to Become a Bust?
Seven months after Travere Therapeutics’ flagship drug received accelerated FDA approval in a rare kidney disease, the molecule has fallen short of the key goal of its confirmatory test. It’s the small molecule’s second Phase 3 failure this year.

Look 4.1 – This Style
Focuses on Men’s Checked
Shirts and Jeans
Focuses on Men’s Checked
Shirts and Jeans